ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Decker, D.
Right arrow Articles by Farkas, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decker, D.
Right arrow Articles by Farkas, D.
Annals of Clinical and Laboratory Science, Vol 25, Issue 1, 52-59
Copyright © 1995 by Association of Clinical Scientists

Articles

Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations

DA Decker, LW Morris, AJ Levine, JE Pettinga, JL Grudzien, and DH Farkas

Paraffin-embedded, formalin-fixed tissue (PEFFT) specimens from a subset of breast cancer patients were analyzed by immunohistochemistry to determine whether or not the presence of P-glycoprotein identified chemotherapy resistance. Two antibodies, C219 (monoclonal) and Ab1 (polyclonal), demonstrated appropriate immunostaining. Retrospectively and prospectively, P-glycoprotein expression was determined from PEFFT of 20 breast cancer biopsies (19 patients with locally advanced or metastatic disease). Immunohistochemical staining was graded for number of positive cells (N0 to N4) and intensity (I0 to I3). The immunostaining N and I of both antibodies were similar. There was no correlation between N, (P = 0.13) or I, (P = 0.67) and chemotherapy response or between N, (P = 0.63) or I, (P = 0.89) and survival. Five patients had residual cancer at repeat biopsy after systemic chemotherapy for locally advanced disease. These specimens had similar N and I as the primary cancer. This assay accurately identifies P-glycoprotein expression in PEFFT and revealed no correlation between expression and chemotherapy response or survival.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson
The Farnesyl Protein Transferase Inhibitor SCH66336 Is a Potent Inhibitor of MDR1 Product P-glycoprotein
Cancer Res., October 1, 2001; 61(20): 7525 - 7529.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Y.-Y. LIU, T.-Y. HAN, A. E. GIULIANO, and M. C. CABOT
Ceramide glycosylation potentiates cellular multidrug resistance
FASEB J, March 1, 2001; 15(3): 719 - 730.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson
In Vitro Flow Cytometry Method to Quantitatively Assess Inhibitors of P-Glycoprotein
Drug Metab. Dispos., May 1, 2000; 28(5): 522 - 528.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. V. Ambudkar, C. O. Cardarelli, I. Pashinsky, and W. D. Stein
Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein
J. Biol. Chem., August 22, 1997; 272(34): 21160 - 21166.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Association of Clinical Scientists.